Psoriasis is a chronic immune-mediated skin disease affecting up to 3% of the population that is associated with a significantly impaired quality of life. Lesional psoriatic skin is primarily characterized by significant Th1- and Th17-mediated inflammation, resulting in increased Janus kinase (JAK) signaling. Ruxolitinib cream (Rux Cream) is a potent, topically applied, selective inhibitor of JAK1 and JAK2 of the JAK-STAT signaling pathway. Treatment with Rux Cream was associated with significant therapeutic benefit in patients with mild to moderate psoriasis with some patients experiencing greater benefit than others. This study aims to identify biomarkers to predict response to Rux Cream in participants with plaque psoriasis from RNA-Seq data.

Novel Genomic Signature Predicts Response to Ruxolitinib Cream in Psoriasis